United Therapeutics (UTHR) Depreciation & Amortization (CF) (2009 - 2026)

United Therapeutics has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $22.6 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) rose 14.14% year-over-year to $22.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.4 million (up 14.36% YoY) and the FY2025 annual result came in at $85.6 million, up 18.07% from the prior year.
• Depreciation & Amortization (CF) declined to $22.6 million in Q1 2026 per UTHR's latest filing, from $22.8 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $22.8 million in Q4 2025 and troughed at $12.5 million in Q1 2022.
• A 5-year average of $16.8 million and a median of $15.0 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) changed 0.0% in 2022, then soared 44.96% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $13.2 million in 2022, then climbed by 3.79% to $13.7 million in 2023, then jumped by 43.8% to $19.7 million in 2024, then advanced by 15.74% to $22.8 million in 2025, then declined by 0.88% to $22.6 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $22.6 million, $22.8 million, and $21.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.